Rujianing (Lerociclib) – Breast Cancer | HongKong DengYue Medicine

  • Generic Name/Brand Name: ​Lerociclib / Rujianing®
  • Indications: Breast Cancer
  • Dosage Form: ​Tablet
  • Specification: 50 mg × 42 tablets
Category: Tags: , ,

Lerociclib Application Scope

It is an oral, selective CDK4/6 inhibitor approved for the treatment of HR+/HER2- advanced or metastatic breast cancer in adults. It can be combined with:

  • Aromatase inhibitors as first-line endocrine therapy

  • Fulvestrant for patients progressing after prior endocrine therapy

It is designed for continuous oral administration, providing sustained target inhibition with a favorable safety profile, including reduced risk of severe neutropenia and diarrhea compared to other CDK4/6 inhibitors.

rujianing lerociclib
rujianing lerociclib

Lerociclib Characteristics

  • Ingredients: Lerociclib Hydrochloride (active ingredient)

  • Properties:​ Oral film-coated tablet

  • Packaging Specification:​ 50 mg × 42 tablets/box

  • Storage:​ Store in a cool, dry place below 25°C, protect from light and moisture

  • Expiry Date: As per manufacturer

  • Executive Standard: ​NMPA-approved standard for oral oncology drugs

  • Approval Number: NMPA Class 1 Innovative Drug (Approved: 2025/05/29)

  • Date of Revision: 2025-05-29

  • Manufacturer: Jiahe Biopharma (Cayman) Holdings Ltd.

Guidelines for the Use of Rujianing

  • Dosage and Administration:

    • Recommended Dose: 50 mg orally, once daily (as per physician’s guidance)

    • Administration: Continuous oral dosing

    • Missed Dose:​ Take as soon as remembered; do not double-dose dose

  • Adverse Reactions:

    • Common Adverse Reactions: Neutropenia, fatigue, nausea

    • Serious Adverse Reactions: Severe neutropenia, thrombocytopenia

  • Contraindications:

    • Hypersensitivity to Lerociclib or excipients

    • Severe hepatic impairment

  • Precautions:

    • Monitor blood counts regularly.

    • Adjust dose in case of hematologic toxicity.

  Lerociclib Interactions

  • Concomitant strong CYP3A4 inhibitors or inducers may alter plasma levels.

  • Avoid live vaccines during treatment.

  • Use caution with other myelosuppressive agents.

 

Note:

  • If there is a new packaging for the drug, the new packaging shall prevail. The above information is sourced from DengYue Medicine.
  •  This content is for reference only. Prescription drugs must be used under a doctor’s guidance and purchased from authorized sources.
Contact Us
Contact Form Demo